<!doctype html><html lang=zh-tw><head><meta charset=utf-8><meta name=description content="at: [[inbox]]
Endocrinology - Obesity - Fast Facts | NEJM Resident 360 Obesity has emerged as a leading public health concern in the last century."><meta property="og:title" content><meta property="og:description" content><meta property="og:type" content="website"><meta property="og:url" content><meta property="og:image" content="https://og-ph6wrfvo1-htlin222.vercel.app/api/blog?templateTitle=Endocrinology - Obesity - Fast Facts | NEJM Resident 360"><title>Endocrinology - Obesity - Fast Facts | NEJM Resident 360</title><meta name=viewport content="width=device-width,initial-scale=1"><link rel="shortcut icon" type=image/png href=https://www.physician.tw//icon.png><link href=https://www.physician.tw/styles.720e2c4835986a3891d6eef3a55faa22.min.css rel=stylesheet><link href=https://www.physician.tw/styles/_light_syntax.86a48a52faebeaaf42158b72922b1c90.min.css rel=stylesheet id=theme-link><script src=https://www.physician.tw/js/darkmode.dfadb738e747a87e78c7144d7267f1bc.min.js></script>
<script src=https://www.physician.tw/js/util.6f22941e242efae60fd84e7c32e874fa.min.js></script>
<link rel=preload href=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.css as=style onload='this.onload=null,this.rel="stylesheet"' integrity=sha384-R4558gYOUz8mP9YWpZJjofhk+zx0AS11p36HnD2ZKj/6JR5z27gSSULCNHIRReVs crossorigin=anonymous><script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.js integrity=sha384-z1fJDqw8ZApjGO3/unPWUPsIymfsJmyrDVWC8Tv/a1HeOtGmkwNd/7xUS0Xcnvsx crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/contrib/auto-render.min.js integrity=sha384-+XBljXPPiv+OzfbB3cVmLHf4hdUFHlWNZN5spNQ7rmHTXpd7WvJum6fIACpNNfIR crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.16.2/dist/contrib/copy-tex.min.js integrity=sha384-ww/583aHhxWkz5DEVn6OKtNiIaLi2iBRNZXfJRiY1Ai7tnJ9UXpEsyvOITVpTl4A crossorigin=anonymous></script>
<script async src=https://unpkg.com/@floating-ui/core@0.7.3></script>
<script async src=https://unpkg.com/@floating-ui/dom@0.5.4></script>
<script async src=https://www.physician.tw/js/popover.f03552ccb84d99ca615d1cfb9abde59e.min.js></script>
<script defer src=https://www.physician.tw/js/code-title.ce4a43f09239a9efb48fee342e8ef2df.min.js></script>
<script defer src=https://www.physician.tw/js/clipboard.2913da76d3cb21c5deaa4bae7da38c9f.min.js></script>
<script defer src=https://www.physician.tw/js/callouts.7723cac461d613d118ee8bb8216b9838.min.js></script>
<script>const SEARCH_ENABLED=!1,LATEX_ENABLED=!0,PRODUCTION=!0,BASE_URL="https://www.physician.tw/",fetchData=Promise.all([fetch("https://www.physician.tw/indices/linkIndex.02120ee5abce9b994b1487466af3b5e4.min.json").then(e=>e.json()).then(e=>({index:e.index,links:e.links})),fetch("https://www.physician.tw/indices/contentIndex.5b83f749048f13c9288e6ddafdf78a71.min.json").then(e=>e.json())]).then(([{index:e,links:t},n])=>({index:e,links:t,content:n})),render=()=>{const e=new URL(BASE_URL),t=e.pathname,n=window.location.pathname,s=t==n;addCopyButtons(),addTitleToCodeBlocks(),addCollapsibleCallouts(),initPopover("https://www.physician.tw",!0);const o=document.getElementById("footer");if(o){const e=document.getElementById("graph-container");if(!e)return requestAnimationFrame(render);e.textContent="";const t=s&&!1;drawGraph("https://www.physician.tw",t,[{"/moc":"#4388cc"}],t?{centerForce:1,depth:-1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.5,linkDistance:1,opacityScale:3,repelForce:1,scale:1.4}:{centerForce:1,depth:1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.6,linkDistance:1,opacityScale:3,repelForce:2,scale:1.2})}},init=(e=document)=>{addCopyButtons(),addTitleToCodeBlocks(),renderMathInElement(e.body,{delimiters:[{left:"$$",right:"$$",display:!0},{left:"$",right:"$",display:!1}],macros:{'’':"'"},throwOnError:!1})}</script><script type=module>
    import { attachSPARouting } from "https:\/\/www.physician.tw\/js\/router.9d4974281069e9ebb189f642ae1e3ca2.min.js"
    attachSPARouting(init, render)
  </script></head><body><div id=search-container><div id=search-space><input autocomplete=off id=search-bar name=search type=text aria-label=搜尋 placeholder="請輸入像是：hypertension 之類的來看沒有沒什麼有趣的🎳"><div id=results-container></div></div></div><script src=https://cdn.jsdelivr.net/npm/flexsearch@0.7.21/dist/flexsearch.bundle.js integrity="sha256-i3A0NZGkhsKjVMzFxv3ksk0DZh3aXqu0l49Bbh0MdjE=" crossorigin=anonymous defer></script>
<script defer src=https://www.physician.tw/js/full-text-search.e6e2e0c213187ca0c703d6e2c7a77fcd.min.js></script><div class=singlePage><header><h1 id=page-title><a href=https://www.physician.tw/>蜥蜴花園🦎🌱🪴🌲</a></h1><div class=spacer></div><div id=search-icon><p>搜尋</p><svg tabindex="0" aria-labelledby="title desc" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 19.9 19.7"><title id="title">搜尋圖示</title><desc id="desc">打開搜尋圖標</desc><g class="search-path" fill="none"><path stroke-linecap="square" d="M18.5 18.3l-5.4-5.4"/><circle cx="8" cy="8" r="7"/></g></svg></div><div class=darkmode><input class=toggle id=darkmode-toggle type=checkbox tabindex=-1>
<label id=toggle-label-light for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="dayIcon" viewBox="0 0 35 35" style="enable-background:new 0 0 35 35"><title>明亮模式</title><path d="M6 17.5C6 16.672 5.328 16 4.5 16h-3C.672 16 0 16.672.0 17.5S.672 19 1.5 19h3C5.328 19 6 18.328 6 17.5zM7.5 26c-.414.0-.789.168-1.061.439l-2 2C4.168 28.711 4 29.086 4 29.5 4 30.328 4.671 31 5.5 31c.414.0.789-.168 1.06-.44l2-2C8.832 28.289 9 27.914 9 27.5 9 26.672 8.329 26 7.5 26zm10-20C18.329 6 19 5.328 19 4.5v-3C19 .672 18.329.0 17.5.0S16 .672 16 1.5v3C16 5.328 16.671 6 17.5 6zm10 3c.414.0.789-.168 1.06-.439l2-2C30.832 6.289 31 5.914 31 5.5 31 4.672 30.329 4 29.5 4c-.414.0-.789.168-1.061.44l-2 2C26.168 6.711 26 7.086 26 7.5 26 8.328 26.671 9 27.5 9zM6.439 8.561C6.711 8.832 7.086 9 7.5 9 8.328 9 9 8.328 9 7.5c0-.414-.168-.789-.439-1.061l-2-2C6.289 4.168 5.914 4 5.5 4 4.672 4 4 4.672 4 5.5c0 .414.168.789.439 1.06l2 2.001zM33.5 16h-3c-.828.0-1.5.672-1.5 1.5s.672 1.5 1.5 1.5h3c.828.0 1.5-.672 1.5-1.5S34.328 16 33.5 16zM28.561 26.439C28.289 26.168 27.914 26 27.5 26c-.828.0-1.5.672-1.5 1.5.0.414.168.789.439 1.06l2 2C28.711 30.832 29.086 31 29.5 31c.828.0 1.5-.672 1.5-1.5.0-.414-.168-.789-.439-1.061l-2-2zM17.5 29c-.829.0-1.5.672-1.5 1.5v3c0 .828.671 1.5 1.5 1.5s1.5-.672 1.5-1.5v-3C19 29.672 18.329 29 17.5 29zm0-22C11.71 7 7 11.71 7 17.5S11.71 28 17.5 28 28 23.29 28 17.5 23.29 7 17.5 7zm0 18c-4.136.0-7.5-3.364-7.5-7.5s3.364-7.5 7.5-7.5 7.5 3.364 7.5 7.5S21.636 25 17.5 25z"/></svg></label><label id=toggle-label-dark for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="nightIcon" viewBox="0 0 100 100" style="enable-background='new 0 0 100 100'"><title>黑暗模式</title><path d="M96.76 66.458c-.853-.852-2.15-1.064-3.23-.534-6.063 2.991-12.858 4.571-19.655 4.571C62.022 70.495 50.88 65.88 42.5 57.5 29.043 44.043 25.658 23.536 34.076 6.47c.532-1.08.318-2.379-.534-3.23-.851-.852-2.15-1.064-3.23-.534-4.918 2.427-9.375 5.619-13.246 9.491-9.447 9.447-14.65 22.008-14.65 35.369.0 13.36 5.203 25.921 14.65 35.368s22.008 14.65 35.368 14.65c13.361.0 25.921-5.203 35.369-14.65 3.872-3.871 7.064-8.328 9.491-13.246C97.826 68.608 97.611 67.309 96.76 66.458z"/></svg></label></div></header><article><h1>Endocrinology - Obesity - Fast Facts | NEJM Resident 360</h1><p class=meta>最後更新於
Feb 23, 2023
<a href=https://github.com/htlin222/garden/tree/hugo/content/Endocrinology%20-%20Obesity%20-%20Fast%20Facts%20%20NEJM%20Resident%20360.md rel=noopener>🪚 編輯原始文件</a></p><ul class=tags></ul><p>at: <a class="internal-link broken">inbox</a></p><a href=#endocrinology---obesity---fast-facts--nejm-resident-360><h1 id=endocrinology---obesity---fast-facts--nejm-resident-360><span class=hanchor arialabel=Anchor># </span>Endocrinology - Obesity - Fast Facts | NEJM Resident 360</h1></a><p>Obesity has emerged as a leading public health concern in the last century. Obesity-related conditions are leading causes of preventable death in the United States. The health effects of obesity are far-reaching and include hypertension, obstructive sleep apnea, osteoarthritis, and cancer. In this section, we review management options for obesity. The following graph shows the age-standardized prevalence trends at the global level and according to sociodemographic index (SDI) quintile from 1980 through 2015 among adults.</p><a href=#prevalence-of-obesity-at-the-global-level-in-adults-according-to-sociodemographic-index-sdi><h3 id=prevalence-of-obesity-at-the-global-level-in-adults-according-to-sociodemographic-index-sdi><span class=hanchor arialabel=Anchor># </span>Prevalence of Obesity at the Global Level in Adults, According to Sociodemographic Index (SDI)</h3></a><p><strong>Shown is the prevalence of obesity at the global level among adults.<br>(Source: Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med 2017.)</strong></p><a href=#classification-of-obesity><h3 id=classification-of-obesity><span class=hanchor arialabel=Anchor># </span>Classification of Obesity</h3></a><p>Although body mass index (BMI) is not a perfect marker of obesity, some organizations use BMI to classify obesity according to the following categories:</p><a href=#classification-of-overweight-and-obesity-by-bmi><h3 id=classification-of-overweight-and-obesity-by-bmi><span class=hanchor arialabel=Anchor># </span>Classification of Overweight and Obesity by BMI</h3></a><table><thead><tr><th>Weight</th><th>BMI (kg/m<sup>2</sup>)</th><th>BMI (kg/m<sup>2</sup>) for Asians</th></tr></thead><tbody><tr><td>Normal weight</td><td>18.5–24.9</td><td>18.5–22.9</td></tr><tr><td>Overweight</td><td>25.0–29.9</td><td>23–26.9</td></tr><tr><td>Obesity class I</td><td>30.0–34.9</td><td>27–32.4</td></tr><tr><td>Obesity class II</td><td>35.0–39.9</td><td>32.5–37.4</td></tr><tr><td>Obesity class III</td><td>>40</td><td>>37.5</td></tr></tbody></table><a href=#body-mass-index-bmi--weight-in-kilograms-divided-by-the-square-of-height-in-meters><h6 id=body-mass-index-bmi--weight-in-kilograms-divided-by-the-square-of-height-in-meters><span class=hanchor arialabel=Anchor># </span>Body mass index (BMI) = weight in kilograms divided by the square of height in meters</h6></a><a href=#pathophysiology><h3 id=pathophysiology><span class=hanchor arialabel=Anchor># </span>Pathophysiology</h3></a><p>The prevalence of obesity has been rising worldwide. This is likely a multifactorial problem, and the postulated factors that have influenced its rise in the last few decades include an increasingly sedentary lifestyle, processed and caloric-dense foods, large portion sizes, and obesogenic environments such as food “deserts” and fast food “islands.”</p><p>On a microscopic level, adipose tissue deposition occurs over time in the subcutaneous and visceral tissue and has several effects including increasing mechanical stress, releasing proinflammatory cytokines, and increasing sympathetic activity. The following figure illustrates the pathophysiology of obesity and its health-related complications.</p><a href=#some-pathways-through-which-excess-adiposity-leads-to-major-risk-factors-and-common-chronic-diseases><h3 id=some-pathways-through-which-excess-adiposity-leads-to-major-risk-factors-and-common-chronic-diseases><span class=hanchor arialabel=Anchor># </span><strong>Some Pathways through Which Excess Adiposity Leads to Major Risk Factors and Common Chronic Diseases</strong></h3></a><p><strong>Common chronic diseases are shown in red boxes. The dashed arrow denotes an indirect association.<br>(Source: Mechanisms, Pathophysiology, and Management of Obesity. N Engl J Med 2017.)</strong></p><p>Some of the health-related effects of obesity are reversible with weight loss. For instance, studies have shown that a 5% weight loss is associated with improvement in pancreatic beta-cell function and insulin sensitivity in liver and the skeletal muscle. A 5%–10% weight loss has been associated with clinically meaningful improvements in obesity-related complications, including hypertension and hyperlipidemia.</p><p>After the initial period of weight loss, patients tend to regain weight because of factors that include:</p><ul><li><p>decreased adherence to diet</p></li><li><p>decreased activity</p></li><li><p>increased endogenous compensatory mechanisms</p></li></ul><a href=#treatment><h3 id=treatment><span class=hanchor arialabel=Anchor># </span>Treatment</h3></a><p>Treatment of obesity is a complex process that depends on the patient’s weight, associated medical conditions, and functional capacity. The main treatment options are lifestyle intervention, pharmacotherapy, and bariatric surgery.</p><p><strong>Lifestyle interventions:</strong> As the first-line option in weight management, lifestyle interventions involve reduced food intake, increased physical activity, and behavioral motivational training. Studies that provide data to support the efficacy of lifestyle interventions include the Finnish Diabetes Prevention Study, Diabetes Prevention Program, and the Look AHEAD study. The table below summarizes guidelines for both weight loss and subsequent maintenance of weight loss from the 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults.</p><p><strong>(Source: Mechanisms, Pathophysiology, and Management of Obesity. N Engl J Med 2017.)</strong></p><p>Counselling patients on weight loss is challenging. The “ABCDEF” approach is one method to consider to guide weight counseling with patients.</p><p>Although dietary modification is key to weight loss and maintaining weight loss, no single dietary strategy has been shown to be clearly superior. Current AHA/ACC guidelines recommend a diet high in vegetables, fruits, whole grains, fish, and legumes, with low intake of sugar, sweetened beverages, and red meats.</p><p><strong>Medical management:</strong> Pharmacotherapy is recommended as an adjunct to dietary modification in patients with a BMI ≥30 or a BMI ≥27 and a weight-related coexisting condition. There are currently 9 medications that have been approved by the U.S. Food and Drug Administration for chronic weight management. The primary effect of these medications is to decrease appetite and improve dietary adherence. Once started on therapy, patients should be assessed for response to treatment. A target weight loss of 3%–5% should be achieved within 3 months, otherwise the medication should be discontinued. The following table reviews these medications and their study findings.</p><a href=#medications-approved-by-the-food-and-drug-administration-for-long-term-weight-management><h3 id=medications-approved-by-the-food-and-drug-administration-for-long-term-weight-management><span class=hanchor arialabel=Anchor># </span>Medications Approved by the Food and Drug Administration for Long-Term Weight Management</h3></a><p>| Drug | Main Mechanism<br>of Action | Dose | Study Duration<br>(weeks) | Mean Weight Loss</p><table><thead><tr><th>kg (%)</th><th>Common Adverse Effects</th><th>Contraindications</th><th></th><th></th><th></th><th></th></tr></thead><tbody><tr><td>Orlistat</td><td>Pancreatic and gastric lipase inhibitor; resulting fat malabsorption reduces net energy intake</td><td>120 mg before meals (three times a day)</td><td>52</td><td>Drug, 8.8 (8.8);</td><td></td><td></td></tr><tr><td>placebo, 5.8 (5.8);</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>PSWL, 2.6</td><td>Oily spotting, flatus with discharge, fecal urgency, oily evacuation, increased defecation, fecal incontinence</td><td>Pregnancy, chronic malabsorption syndrome, cholestasis</td><td></td><td></td><td></td><td></td></tr><tr><td>Liraglutide</td><td>GLP-1 agonist; delays gastric emptying to reduce food intake</td><td>Starting dose, 0.6 mg given subcutaneously once daily;</td><td></td><td></td><td></td><td></td></tr><tr><td>dose increased weekly by 0.6 mg as tolerated to reach 3.0 mg</td><td>56</td><td>Drug, 8.4 (8.0);</td><td></td><td></td><td></td><td></td></tr><tr><td>placebo, 2.8 (2.6);</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>PSWL, 5.3</td><td>Nausea, vomiting, constipation, hypoglycemia, diarrhea, headache, fatigue, dizziness, abdominal pain, increased lipase levels</td><td>Pregnancy, personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2</td><td></td><td></td><td></td><td></td></tr><tr><td>Semaglutide</td><td>GLP-1 agonist; delays gastric emptying to reduce food intake</td><td>Starting dose, 0.25 mg given subcutaneously once weekly for first 4 weeks, with the dose increased every 4 weeks to reach the maintenance dose of 2.4 mg</td><td>68</td><td>Drug, 15.3 (14.9);</td><td></td><td></td></tr><tr><td>placebo, 2.6 (2.4);</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>PSWL, 12.7</td><td>Nausea, vomiting, constipation, hypoglycemia, diarrhea, headache, fatigue, dizziness, abdominal pain, increased lipase levels</td><td>Pregnancy, personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2</td><td></td><td></td><td></td><td></td></tr><tr><td>Phentermine– topiramate</td><td>Norepinephrine-releasing agent (phentermine), GABA receptor modulation (topiramate); decreases appetite to reduce food intake</td><td>Starting dose, 3.75 mg/ 23 mg for 2 wk; recommended</td><td></td><td></td><td></td><td></td></tr><tr><td>dose, 7.5 mg/</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>46 mg;</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>maximum dose, 15 mg/92 mg</td><td>56</td><td>Drug, 8.1 (7.8)</td><td></td><td></td><td></td><td></td></tr><tr><td>at recom-</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>mended dose,</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>10.2 (9.8) at</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>maximum dose;</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>placebo, 1.4 (1.2);</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>PSWL, 8.8</td><td>Insomnia,</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>dry mouth, constipation, paresthesias, dizziness, dysgeusia</td><td>Pregnancy, hyperthyroidism, glaucoma, MAOIs, hypersensitivity</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>to sympatho-</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>mimetic amines</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Naltrexone– bupropion</td><td>Opioid antagonist (naltrexone), dopamine and norepinephrine reuptake inhibitor (bupropion);</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>acts on CNS pathways to reduce food intake</td><td>1 tablet (8 mg of naltrexone and 90 mg of bupropion) daily for 1 wk; dose subsequently increased each wk by 1 tablet per day until maintenance dose of</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>2 tablets twice</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>a day at wk 4</td><td>56</td><td>Drug, 6.2 (6.4);</td><td></td><td></td><td></td><td></td></tr><tr><td>placebo, 1.3 (1.2);</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>PSWL, 5.0</td><td>Nausea, constipation, headache, vomiting, dizziness, insomnia,</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>dry mouth,</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>diarrhea</td><td>Uncontrolled hypertension, seizure disorders, anorexia nervosa or bulimia,</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>drug or alcohol</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>withdrawal,</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>use of MAOIs,</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>long-term</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>opioid use,</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>pregnancy</td><td></td><td></td><td></td><td></td><td></td><td></td></tr></tbody></table><a href=#abbreviations-pswl-placebo-subtracted-weight-loss-cns-central-nervous-system-gaba-gamma-aminobutyric-acid-glp-1-glucagon-like-peptide-1-5ht2c-5-hydroxytryptamine-2c-maoi-monoamine-oxidase-inhibitors><h6 id=abbreviations-pswl-placebo-subtracted-weight-loss-cns-central-nervous-system-gaba-gamma-aminobutyric-acid-glp-1-glucagon-like-peptide-1-5ht2c-5-hydroxytryptamine-2c-maoi-monoamine-oxidase-inhibitors><span class=hanchor arialabel=Anchor># </span>Abbreviations: PSWL, placebo-subtracted weight loss; CNS, central nervous system; GABA, gamma-aminobutyric acid; GLP-1, glucagon-like peptide 1; 5HT2C, 5-hydroxytryptamine 2C; MAOI, monoamine oxidase inhibitors</h6></a><p>(Adapted from: Mechanisms, Pathophysiology, and Management of Obesity. N Engl J Med 2017.)</p><p><strong>Surgical management:</strong> Weight loss through surgery should be considered in patients with BMI ≥40 or a BMI ≥35 and a coexisting condition (e.g., type 2 diabetes, sleep apnea, osteoarthritis). Currently, the following four types of weight-loss surgery are performed most often in the United States:</p><ul><li><p>gastric banding</p></li><li><p>sleeve gastrectomy</p></li><li><p>Roux-en-Y gastric bypass</p></li><li><p>biliopancreatic diversion with duodenal switch</p></li></ul><p>Read about the advantages and disadvantages of these surgical options here.</p><p><a class="internal-link broken">inbox</a></p></article><hr><div class=page-end id=footer><div class=backlinks-container><h3>↩️ 反向連結</h3><ul class=backlinks><li><a href=/all-list-of-resident360/ data-ctx="Endocrinology - Obesity - Fast Facts  NEJM Resident 360" data-src=/all-list-of-resident360 class=internal-link>all list of resident360</a></li></ul></div><div><script async src=https://cdn.jsdelivr.net/npm/d3@6.7.0/dist/d3.min.js integrity="sha256-+7jaYCp29O1JusNWHaYtgUn6EhuP0VaFuswhNV06MyI=" crossorigin=anonymous></script><h3>🤯互動圖</h3><div id=graph-container></div><style>:root{--g-node:var(--secondary);--g-node-active:var(--primary);--g-node-inactive:var(--visited);--g-link:var(--outlinegray);--g-link-active:#5a7282}</style><script src=https://www.physician.tw/js/graph.2d9e48dbe7ea47c0ef1c58296ce14448.js></script></div></div><div><div id=disqus_thread></div><script type=application/javascript>window.disqus_config=function(){},function(){if(["localhost","127.0.0.1"].indexOf(window.location.hostname)!=-1){document.getElementById("disqus_thread").innerHTML="Disqus comments not available by default when the website is previewed locally.";return}var t=document,e=t.createElement("script");e.async=!0,e.src="//physician.disqus.com/embed.js",e.setAttribute("data-timestamp",+new Date),(t.head||t.body).appendChild(e)}()</script><noscript>Please enable JavaScript to view the <a href=https://disqus.com/?ref_noscript>comments powered by Disqus.</a></noscript><a href=https://disqus.com class=dsq-brlink>comments powered by <span class=logo-disqus>Disqus</span></a></div><div id=contact_buttons><footer><p>本網站是由 Hsieh-Ting Lin 以❤️ 用 <a href=https://github.com/jackyzha0/quartz>Quartz</a>這個酷東西種出來🪴 , © 2023</p><ul><li><a href=https://www.physician.tw/>🏠首頁</a></li><li><a href=https://www.facebook.com/Tim.H.Lin>Facebook</a></li><li><a href=https://twitter.com/htlin222>Twitter</a></li><li><a href=https://github.com/htlin222>GitHub</a></li><li><a href=https://htlin.site>Blog</a></li><li><a href=https://medium.com/@hsieh-ting-lin>Medium</a></li></ul></footer></div></div></body></html>